Loading company…
PersonGen develops CAR-T and other cellular immunotherapies for cancer.
Established in 2010 and based in Suzhou, China, PersonGen researches CAR-T and other cellular immunotherapies. Its pipeline includes cell therapies and antibodies, with some products in clinical trials for blood cancers and solid tumors. In January 2026, the company closed Series B+ funding from Xingtai Capital to advance clinical research and industrialization.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in